Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Hemic or immune system
Reexamination Certificate
2010-03-30
2011-12-13
Belyavskyi, Michail (Department: 1644)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Hemic or immune system
Reexamination Certificate
active
08075921
ABSTRACT:
Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.
REFERENCES:
patent: 5624823 (1997-04-01), Sachs et al.
patent: 5747034 (1998-05-01), de Boer et al.
patent: 5756085 (1998-05-01), Sykes et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5858358 (1999-01-01), June et al.
patent: 5861310 (1999-01-01), Freeman et al.
patent: 5869050 (1999-02-01), de Boer et al.
patent: 5883223 (1999-03-01), Gray
patent: 5948893 (1999-09-01), June et al.
patent: 5958403 (1999-09-01), Strom et al.
patent: 5958671 (1999-09-01), Glimcher et al.
patent: 6001973 (1999-12-01), Strom et al.
patent: 6063772 (2000-05-01), Tam
patent: 6129916 (2000-10-01), Chang
patent: 6150337 (2000-11-01), Tam
patent: 6231893 (2001-05-01), Singhal
patent: 90/05541 (1990-05-01), None
patent: 94/28912 (1994-12-01), None
patent: 94/29436 (1994-12-01), None
patent: 95/33823 (1995-12-01), None
patent: 98/33891 (1998-08-01), None
patent: 98/47531 (1998-10-01), None
patent: 99/24045 (1999-05-01), None
patent: 03/004625 (2003-01-01), None
patent: 03/038062 (2003-05-01), None
Ferraresso et al., Transplantation, 1993, vol. 55, pp. 888-894.
Slavik et al., J. of Immunology, 2001, pp. 3201-3209.
Aarvak et al., “Change in the Th1, Th2 Phenotype of Memory T-Cell Clones from Rheumatoid Arthritis Synovium”, Scand. J. Immunol. 50(1), pp. 1-9, 1999.
Assenmacher et al., “Commitment of Individual Th1-Like Lymphocytes to Expression of IFN-(Versus II-4 and IL-10: Selective Induction of IL-10 by Sequential Stimulation of Naive Th Cells with IL-12 and IL-4”, J. Immunol., 161(6), pp. 2825-2832 (1998).
Bradley et al., “The Cytokines II-4, IFN-g, and IL-12 Regulate the Development of Subsets of Memory Effector Helper T Cells in Vitro”, J. Immunol., 155(4), pp. 1713-1723 (1995).
Brinkmann et al., “TCR-independent Activation of human CD4+ 45RO T Cells by AntiCD28 plus IL-2: Induction of Clonal Expansion and Priming for a TH2 Phenotype,” J. Immunol. 156(11):4100-4106, 1996.
Demeure et al, “In Vitro Maturation of Human Neonatal CD$ T Lymphocytes. II. Cytokines present at Priming Modulate the Development of Lymphokine Production,” J. Immuno. 152(10):4775-4782, 1994.
Fowler, et al., “Allospecific CD4+, Tc1/Tc2 Populations in Murine GVL:Type I Cells Generate GVL and Type II Cells Abrogate GVL,” Biol. Blood Marrow Transplant. 2(3):118-125, 1996.
Fowler et al., “Donor CD4-Enriched Cells of Th2 Cytokine Phenotype Regulate Graft-Versus-Host Disease Without Impairing Allogeneic Engraftment in Sublethally Irradiated Mice,” Blood 84(10):3540-3549, 1994.
Fowler et al., “Donor Lymphoid Cells of Th2 Cytokine Phenotype Reduce Lethal Graft Versus Host Disease and Facilitate Fully Allogenic Cell Transfers in Sublethally Irradiated Mice,” Prog. Clin. Biol. REs. 389:533-540, 1994.
Fowler, et al., “Th2 and Tc2 Cells in the Regulation of GVHD, GVL, and Graft Rejection: Consideration for the Allogeneic Transplantation Therapy of Leukemia and Lymphoma,” Leukemia and Lymphoma 38(3-4):221-234, 2000.
Garlie et al., “T Cells Coactivated with Immobilized Anti-CD3 and Anti-CD28 as Potential Immunotherapy for Cancer,” J. Immunother. 22:336-345, 1999.
Gerosa, et al., “Interleukin-12 Primes Human CD4 and CD8 T Cell Clones for High Production of Both Interferon-GAmma and Interleukin-10,” J. Exp. Med. 183(6):2559-2569, 1996.
Hu-Li et al., “In differentiated CD4+ T ells, Interleukin 4 Production is cytokine-Automonous, Whereas Interferon Production is Cytokin-Dependent,” Oric, Batk, Acad, Scu. USA 94:3189-3194, 1997.
Kane et al., “Akt Provides the CD28 Costimulatory Signal for Up-Regulation of IL-2 and IIFN-(but not TH2 Cytokines,” Nature Immunol. 2(1):37-44, 2001.
Keralavarma et al., “Improved ‘Suicide’ Retroviral Vector Containing Mutant HSV-TK Gene Confers Increased Sensitivity to Gancyclovir,” Blood 94(supp. 12):329b, 1999.
Levine et al., “Large-Scale Produciton of CD4+ T Cells from HIV-1-Infected Donors After CD3/CD28 Costimulation,” J. Hematother. 7:437-448, 1998.
Lovett-Racke et al., “Decreased Dependence of Myelin Basic Protin-Reactive T Cells on CD28-Mediated Costimulation in Multiple Sclerosis Patients,” J. Clin. Invest. 101(4):725-730, 1998.
Lum, et al., “Immune Modulation in Cancer Patients After Adoptive Tranfer of Anti-CD3/Anti-CD28—Costimulated T Cell—Phase 1 Clinical Trial,” J. Immunother. 24:408-419, 2001.
Nakamura et al., “Polarization of II-4- and IFN-Gamma-Producing CD4+ T Cells FollowingActivation of Naive CD4- T Cells,” J. Immunol. 158(3):1085-1094, 1997.
Noble, et al., “Early Th1.Th2 Cell Polarization in the Absence of IL-4 and II-12: T Cell Receptor Signaling Regulates the REsponse to Cytokines in CD4 and CD8 T Cells,” Eur. J. Immunol. 31:2227-2235, 2001.
Ohta et al., “Manipulation of Th1/Th2 Balance in Vivo by Adoptive Transfer of Antigen-Specific Th1 abnd Th2 Cells,” J. Immunological Methods 209:85-92, 1997.
Palm et al., “Co-Developmentof Naive CD4+ Cells Towards T Helper Type or T Helper Type 2 Cells Induced by a Combination of IL-12 and IL-4,” Immunogiol. 196:475-484, 1996/97.
Parada et al., “Synergistic Activation of CD4+ T Cells by I1-16 and IL-2,” J. Immunol. 160:2115-2120, 1998.
Petrus et al., “An Immunoablative Regimen of Fludarabine and Cyclophosphamide Prevents Fully MHC-Mismatched Murine Marrow Graft Rejection Independent of GVHD,” Biol. Blood Marrow Transplant 6(2A):182-189, 2000.
Riley, et al., “Naive and Memory CD4 T Cells Differ in THeir Susceptibilities to Human Immunodeficiency Virus Type 1 Infection following CD28 Costimulation: Implications for Transmission and Pathogenesis,” J. Virol. 72(10):8273-8280, 1998.
Sad, et al., “Cytokine-Induced Differentiation of Precursor Mouse CD8+ T Cells into Cytotoxic CD8+ T Celss Secreting Th1 or Th2 Cytokines,” Immunity 2(3):271-279, 1994.
Sad, et al., “Single IL-2-Secreting Precursor CD4 T Cell can Develop INto Either Th1 or Th2 Cytokine Secretion Phenotype,” J. Immuno. 153(8):3514-3522, 1999.
Schmitt et al., “Differential Effects of Interleukin-12 on the Development of Naive Mouse CD4+ T Cells,” Eur. J. Immunol. 24:343-347, 1994.
Seder, et al., “High-dose IL-2 and IL-15 Enhance the in Vitro Priming of Naive CD4+ T Cells for IFN-Gamma but Have Differential Effects on Priming for IL-4,” J. Immunol. 156(7):2413-2422, 1996.
Skea, et al., “The Selective Expansion of Functional T Cell Subsets,” J. Hematother. Stem Cell Res. 8(5):525-538, 1999.
Sornasse et al., “Differentiation and Stability of T Helper 1 and 2 Cells Derived from Naive Human Neonatal CD4+ T Cells, Analyzed at the Single-Cell Level,” J. Exp. Med. 184:473-483, 1996.
Syme, et al. “Effects of Cytokines on the Culture and Differentiation of Dentritic Cells in Vitro,” J. Hematother. Stem Cel Res. 10:43-51, 2001.
Powell, J.D. et al, Inhibition of Cell Cycle Progression by Rapamycin Induces T Cell Clonal Anergy Even in the Presnece of Costimulation, The Journal of Immunology, 1999, 162: 2775-2784.
Erard et al. “Presence or Absence of TGF-b Determines IL-4-Induced Generation of Type 1 or Type 2 CD8 T Cell Subsets” The Journal of Immunology, 1999, 162:: 209-214.
Fowler et al. “CD8+ T Cel
Fowler Daniel H.
Gress Ronald E.
June Carl
Jung Unsu
Levine Bruce
Belyavskyi Michail
Corless Peter F.
Edwards Wildman Palmer LLP
The Trustees of the University of Pennsylvania
The United States of America as represented by the Secretary of
LandOfFree
Rapamycin-resistant T cells and therapeutic uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rapamycin-resistant T cells and therapeutic uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rapamycin-resistant T cells and therapeutic uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4265287